Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Envoy MedicalCOCH -7.71%24 Buyback Yield % is -68.65 as of Jul. 19, 2026. GuruFocus rates COCH with a GF Score™ of 24/100 and a GF Value™ of $1.13 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 347 Medical Devices & Instruments companies, Envoy Medical ranks worse than 90.78% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for Envoy Medical's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
COCH vs SRTS, QTI, MDAI: Buyback Yield % Comparison
For the Medical Devices subindustry, Envoy Medical's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Envoy Medical Buyback Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Envoy Medical's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Envoy Medical's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Envoy Medical (COCH) has a Buyback Yield % of -68.65 as of Jul. 19, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Envoy Medical and its competitors. According to the industry distribution chart, Envoy Medical ranks #315 out of 347 companies in the Medical Devices & Instruments industry, placing it in the top 90.8%.
Is Envoy Medical's Buyback Yield % too high?
Envoy Medical's current Buyback Yield % is -68.65. Based on the distribution chart, Envoy Medical ranks #315 out of 347 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Envoy Medical has a GF Score™ of 24/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Envoy Medical's Buyback Yield % compare to SRTS and QTI?
According to the Medical Devices & Instruments industry distribution chart, Envoy Medical ranks #315 out of 347 companies for Buyback Yield %. This places Envoy Medical in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Medical Devices & Instruments company?
A good Buyback Yield % depends on the Medical Devices & Instruments industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Envoy Medical and its competitors. Envoy Medical's current Buyback Yield % is -68.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Envoy Medical stock overvalued right now?
Based on GuruFocus' analysis, Envoy Medical (COCH) is currently considered Possible Value Trap. The stock's GF Value™ is $1.13, compared to a current price of $0.70 — trading 37.9% below its estimated fair value. The current Buyback Yield % is -68.65. Envoy Medical's overall GF Score™ is 24/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Envoy Medical (COCH), the current Buyback Yield % is -68.65 as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Envoy Medical (COCH) Overvalued in 2026?
Based on GuruFocus' analysis, Envoy Medical stock appears to be undervalued.
The current stock price of $0.70 is trading 37.9% below its estimated GF Value™ of $1.13.
GuruFocus considers Envoy Medical to be Possible Value Trap.
Key valuation signals for COCH:
Buyback Yield %: -68.65
GF Value™: $1.13 vs. price of $0.70 (37.9% below fair value)
No single metric tells the full story. See the COCH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Envoy Medical Inc is a hearing health company focused on providing medical technologies across the hearing loss spectrum. Its product portfolio comprises: the Esteem FI-AMEI, a fully implanted active middle ear implant (FI -AMEI) that works with the ear's natural anatomy, and is FDA-approved for adults with moderate to severe sensorineural hearing loss; and Acclaim CI, an investigational cochlear implant under development. The company derives all of its revenue substantially from the sale of the Esteem FI-AMEI implants and their replacement components. It has one reportable segment: hearing.
24GF Score
Get the complete analysis for COCH
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
COCH has been successfully added to your 
